Medicine Mexicor
Pharmacotherapeutic group
Cardiac drugs
ATX code C01E B
Content
Active substance: ethyl methylhydroxypyridine succinate; 1 ml of solution contains ethyl methylhydroxypyridine succinate – 50 mg;
Excipients: succinic acid, disodium edetate, water for injections.
Medicinal form
Solution for injections
The main physical and chemical properties: clear, colorless or slightly colored liquid.
Indications
In complex therapy: acute myocardial infarction (from the first day);
ischemic stroke; dyscirculatory encephalopathy (including atherosclerotic genesis);
mild and moderate cognitive disorders of various genesis.
Contraindications
Increased individual sensitivity to the drug, liver or kidney failure.
Method of administration and dosage
It is administered intravenously or intramuscularly for 14 days against the background of traditional therapy of myocardial infarction. In the first 5 days, to achieve the maximum effect, Mexikor® should be administered intravenously, in the next 9 days, the drug can be administered intramuscularly. The drug is administered intravenously by drip infusion, slowly (to avoid side effects) in 100-150 ml of 0.9% sodium chloride solution or 5% dextrose (glucose) solution over 30-90 minutes. If necessary, a slow jet injection of the drug lasting at least 5 minutes is possible. Administer the drug (intravenously or intramuscularly) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg, a single dose is 2-3 mg/kg of body weight. The maximum daily dose should not exceed 800 mg, a single dose should not exceed 250 mg.
For more detailed information, read the patient information leaflet